Oxford BioMedica (OXB LN) £20.5m raised to fund bioprocessing expansion | Raven Russia Ltd (RUS LN) Good results – high yields | Realm Therapeutics (RLM LN) Disappointing Allergic Conjunctivitis data, Atopic Dermatitis on track | Vectura Group (VEC LN) Pathway clarified for VR315 US, clinical endpoint study required
12 Mar 2018
Morning Song
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Song
- Published:
12 Mar 2018 -
Author:
N+1 Singer Team -
Pages:
10
Oxford BioMedica (OXB LN) £20.5m raised to fund bioprocessing expansion | Raven Russia Ltd (RUS LN) Good results – high yields | Realm Therapeutics (RLM LN) Disappointing Allergic Conjunctivitis data, Atopic Dermatitis on track | Vectura Group (VEC LN) Pathway clarified for VR315 US, clinical endpoint study required